Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2016, Article ID 6760710, 7 pages
http://dx.doi.org/10.1155/2016/6760710
Review Article

Type 2 Diabetes and ADP Receptor Blocker Therapy

1Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 59 Martin, Slovakia
2National Center of Hemostasis and Thrombosis, Department of Hematology and Blood Transfusion, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 59 Martin, Slovakia

Received 15 July 2015; Accepted 4 October 2015

Academic Editor: Andreas Melidonis

Copyright © 2016 Matej Samoš et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Aronson, Z. Bloomgarden, and E. J. Rayfield, “Potential mechanisms promoting restenosis in diabetic patients,” Journal of the American College of Cardiology, vol. 27, no. 3, pp. 528–535, 1996. View at Publisher · View at Google Scholar · View at Scopus
  2. D. Tschoepe, P. Roesen, L. Kaufmann et al., “Evidence for abnormal platelet glycoprotein expression in diabetes mellitus,” European Journal of Clinical Investigation, vol. 20, no. 2, pp. 166–170, 1990. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Kubisz, P. Chudý, J. Staško et al., “Circulating vascular endothelial growth factor in the normo- and/or microalbuminuric patients with type 2 diabetes mellitus,” Acta Diabetologica, vol. 47, no. 2, pp. 119–124, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Chudý, D. Kotuličová, J. Staško, and P. Kubisz, “The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria,” Blood Coagulation & Fibrinolysis, vol. 22, no. 6, pp. 493–498, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. E. A. Amsterdam, N. K. Wenger, R. G. Brindis et al., “2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,” Circulation, vol. 130, no. 25, pp. 2354–2394, 2014. View at Publisher · View at Google Scholar
  6. M. Roffi, C. Patrono, J.-P. Collet et al., “2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation,” European Heart Journal, 2015. View at Publisher · View at Google Scholar
  7. P. G. Steg, S. K. James, D. Atar et al., “ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation,” European Heart Journal, vol. 33, no. 20, pp. 2569–2619, 2012. View at Publisher · View at Google Scholar
  8. D. Erlinge, C. Varenhorst, O. Ö. Braun et al., “Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo,” Journal of the American College of Cardiology, vol. 52, no. 24, pp. 1968–1977, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. D. J. Angiolillo, E. Bernardo, M. Sabaté et al., “Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease,” Journal of the American College of Cardiology, vol. 50, no. 16, pp. 1541–1547, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Tang, M. P. Li, H. H. Zhou, and X. P. Chen, “Platelet inhibition agents: current and future P2Y12 receptor antagonists,” Current Vascular Pharmacology, vol. 13, no. 5, pp. 566–577, 2015. View at Publisher · View at Google Scholar
  11. P. Savi and J.-M. Herbert, “Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis,” Seminars in Thrombosis and Hemostasis, vol. 31, no. 2, pp. 174–183, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Yusuf, F. Zhao, S. R. Mehta, S. Chrolavicius, G. Tognoni, and K. K. Fox, “Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation,” The New England Journal of Medicine, vol. 345, no. 7, pp. 494–502, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Patti, G. Colonna, V. Pasceri, L. L. Pepe, A. Montinaro, and G. Di Sciascio, “Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study,” Circulation, vol. 111, no. 16, pp. 2099–2106, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. E. I. Lev, R. Kornowski, H. Vaknin-Assa et al., “Effect of clopidogrel pretreatment on angiographic and clinical outcomes in patients undergoing primary percutaneous coronary intervention for ST-elevation acute myocardial infarction,” The American Journal of Cardiology, vol. 101, no. 4, pp. 435–439, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. D. J. Angiolillo, P. Capranzano, B. Desai et al., “Impact of P2Y12 inhibitory effects induced by clopidogrel on platelet procoagulant activity in type 2 diabetes mellitus patients,” Thrombosis Research, vol. 124, no. 3, pp. 318–322, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Cuisset, C. Frere, J. Quilici et al., “High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome,” Journal of Thrombosis and Haemostasis, vol. 4, no. 3, pp. 542–549, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. P. A. Gurbel, K. P. Bliden, K. Guyer et al., “Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING study,” Journal of the American College of Cardiology, vol. 46, no. 10, pp. 1820–1826, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. P. A. Gurbel, K. P. Bliden, W. Samara et al., “Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST study,” Journal of the American College of Cardiology, vol. 46, no. 10, pp. 1827–1832, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. I. Iakovou, T. Schmidt, E. Bonizzoni et al., “Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents,” The Journal of the American Medical Association, vol. 293, no. 17, pp. 2126–2130, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. I. A. Ferreira, K. L. Eybrechts, A. I. M. Mocking, C. Kroner, and J.-W. N. Akkerman, “IRS-1 mediates inhibition of Ca2 mobilization by insulin via the inhibitory G-protein Gi,” The Journal of Biological Chemistry, vol. 279, no. 5, pp. 3254–3264, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. D. J. Angiolillo, E. Bernardo, C. Ramírez et al., “Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment,” Journal of the American College of Cardiology, vol. 48, no. 2, pp. 298–304, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. D. J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo et al., “Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment,” Diabetes, vol. 54, no. 8, pp. 2430–2450, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. I. A. Ferreira, A. I. M. Mocking, M. A. H. Feijge et al., “Platelet inhibition by insulin is absent in type 2 diabetes mellitus,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 2, pp. 417–422, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Goldstein, A. Simpson, and P. Saenger, “Hepatic drug metabolism is increased in poorly controlled insulin-dependent diabetes mellitus,” Acta Endocrinologica, vol. 123, no. 5, pp. 550–556, 1990. View at Google Scholar · View at Scopus
  25. T. Kudo, T. Shimada, T. Toda et al., “Altered expression of CYP in TSOD mice: a model of type 2 diabetes and obesity,” Xenobiotica, vol. 39, no. 12, pp. 889–902, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. D. Patoine, M. Petit, S. Pilote, F. Picard, B. Drolet, and C. Simard, “Modulation of CYP3a expression and activity in mice models of type 1 and type 2 diabetes,” Pharmacology Research & Perspectives, vol. 2, no. 6, 2014. View at Publisher · View at Google Scholar
  27. M. Samoš, R. Šimonová, F. Kovář et al., “Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis,” The American Journal of Emergency Medicine, vol. 32, no. 5, pp. 461–465, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. S. R. Steinhubl, P. B. Berger, J. Tift Mann III et al., “Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial,” The Journal of the American Medical Association, vol. 288, no. 19, pp. 2411–2420, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. S. R. Mehta, J.-P. Bassand, S. Chrolavicius et al., “Dose comparisons of clopidogrel and aspirin in acute coronary syndromes,” The New England Journal of Medicine, vol. 363, no. 10, pp. 930–942, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. S. D. Wiviott, E. Braunwald, C. H. McCabe et al., “Prasugrel versus clopidogrel in patients with acute coronary syndromes,” The New England Journal of Medicine, vol. 357, no. 20, pp. 2001–2015, 2007. View at Publisher · View at Google Scholar
  31. M. T. Roe, P. W. Armstrong, K. A. A. Fox et al., “Prasugrel versus clopidogrel for acute coronary syndromes without revascularization,” The New England Journal of Medicine, vol. 367, no. 14, pp. 1297–1309, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. D. Alexopoulos, G. Dimitropoulos, P. Davlouros et al., “Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of cyp2c192 genotyping,” JACC: Cardiovascular Interventions, vol. 4, no. 4, pp. 403–410, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Silvano, C. F. Zambon, G. De Rosa et al., “A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty,” Journal of Thrombosis and Thrombolysis, vol. 31, no. 2, pp. 233–234, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. G. Cayla, T. Cuisset, J. Silvain et al., “Prasugrel monitoring and bleeding in real world patients,” The American Journal of Cardiology, vol. 111, no. 1, pp. 38–44, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. L. Bonello, M. Pansieri, J. Mancini et al., “High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes,” Journal of the American College of Cardiology, vol. 58, no. 5, pp. 467–473, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Samoš, M. Fedor, F. Kovář et al., “Prasugrel loading dose in diabetic patients with acute STEMI—always sufficiently effective? Observation in two cases and review of current knowledge,” Cor et Vasa, vol. 56, no. 5, pp. e388–e395, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. D. Alexopoulos, C. Vogiatzi, K. Stavrou et al., “Diabetes mellitus and platelet reactivity in patients under prasugrel or ticagrelor treatment: an observational study,” Cardiovascular Diabetology, vol. 14, article 68, 2015. View at Publisher · View at Google Scholar
  38. R. F. Storey, K. G. Oldroyd, and R. G. Wilcox, “Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes,” Thrombosis and Haemostasis, vol. 85, no. 3, pp. 401–407, 2001. View at Google Scholar · View at Scopus
  39. R. A. Harrington, G. W. Stone, S. McNulty et al., “Platelet inhibition with cangrelor in patients undergoing PCI,” The New England Journal of Medicine, vol. 361, no. 24, pp. 2318–2329, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. D. L. Bhatt, A. M. Lincoff, C. M. Gibson et al., “Intravenous platelet blockade with cangrelor during PCI,” The New England Journal of Medicine, vol. 361, no. 24, pp. 2330–2341, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. D. L. Bhatt, G. W. Stone, K. W. Mahaffey et al., “Effect of platelet inhibition with cangrelor during PCI on ischemic events,” The New England Journal of Medicine, vol. 368, no. 14, pp. 1303–1313, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. P. G. Steg, D. L. Bhatt, C. W. Hamm et al., “Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data,” The Lancet, vol. 382, no. 9909, pp. 1981–1992, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. R. F. Storey, S. Husted, R. A. Harrington et al., “Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes,” Journal of the American College of Cardiology, vol. 50, no. 19, pp. 1852–1856, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. L. Wallentin, R. C. Becker, A. Budaj et al., “Ticagrelor versus clopidogrel in patients with acute coronary syndromes,” The New England Journal of Medicine, vol. 361, no. 11, pp. 1045–1057, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. D. Alexopoulos, I. Xanthopoulou, E. Mavronasiou et al., “Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetes,” Diabetes Care, vol. 36, no. 8, pp. 2211–2216, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Laine, C. Frère, R. Toesca et al., “Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome. A pharmacodynamic randomised study,” Thrombosis and Haemostasis, vol. 111, no. 2, pp. 273–278, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. A. R. Harper and M. J. Price, “Platelet function monitoring and clopidogrel,” Current Cardiology Reports, vol. 15, article 321, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. J. Geiger, J. Brich, P. Hönig-Liedl et al., “Specific impairment of human platelet P2YAC ADP receptor-mediated signaling by the antiplatelet drug clopidogrel,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 8, pp. 2007–2011, 1999. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Fedor, M. Samoš, R. Šimonová et al., “Monitoring the efficacy of ADP inhibitor treatment in patients with acute STEMI post-PCI by VASP-P flow cytometry assay,” Clinical and Applied Thrombosis/Hemostasis, vol. 21, no. 4, pp. 334–338, 2015. View at Publisher · View at Google Scholar
  50. J. W. Smith, S. R. Steinhubl, A. M. Lincoff et al., “Rapid platelet-function assay: an automated and quantitative cartridge-based method,” Circulation, vol. 99, no. 5, pp. 620–625, 1999. View at Publisher · View at Google Scholar · View at Scopus
  51. M. J. Price, P. B. Berger, P. S. Teirstein et al., “Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial,” The Journal of the American Medical Association, vol. 305, no. 11, pp. 1097–1105, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. J.-P. Collet, T. Cuisset, G. Rangé et al., “Bedside monitoring to adjust antiplatelet therapy for coronary stenting,” The New England Journal of Medicine, vol. 367, no. 22, pp. 2100–2109, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. N. Paarup Dridi, P. I. Johansson, J. T. Lønborg et al., “Tailored antiplatelet therapy to improve prognosis in patients exhibiting clopidogrel low-response prior to percutaneous coronary intervention for stable angina or non-ST elevation acute coronary syndrome,” Platelets, vol. 26, no. 6, pp. 521–529, 2015. View at Publisher · View at Google Scholar